Johnson & Johnson.
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
- Reports this week
- 13
- Active events
- 14
- Connections
- 553
What's happening
Active this week
-
P&G, Johnson & Johnson, and Coca-Cola are noted as dividend growth stocks, coinciding with SEC requirements for fiduciaries to prioritize interests.Well supported10 reports
-
Johnson & Johnson separated its Consumer Health business into Kenvue on August 25, 2025.Well supported16 reports
-
Johnson & Johnson, UnitedHealth Group, and Intuitive Surgical are noted as major players in the high-volume U.S. healthcare sector.Well supported14 reports1 development inside
-
Healthcare architecture is rapidly changing, with robotic procedures underway in Riyadh involving major players like Johnson & Johnson, Mayo Clinic, and Cleveland Clinic.Some support1 report
-
The CBO reported an $8.8 billion handout in OBBB, which weakened Medicare drug price negotiation. Bryan Steil voted for the bill benefiting Big Pharma, after receiving donations from lobbyists.Some support1 report
-
Johnson & Johnson announced successful Phase 2 trial data for CARVYKTI in the multiple myeloma therapy market.Some support1 report
-
Johnson & Johnson and Recordati Industria Chimica E Farmaceutica are noted as large-cap healthcare companies.Some support1 report
-
Johnson & Johnson, JPMorgan Chase, and AbbVie are dividend payers in the VYM fund.Some support1 report
-
Nanobiotix and Johnson & Johnson are collaborating on nanotherapeutics. Laurent Levy is the CEO of Nanobiotix.Some support1 report
-
RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.Speculative1 report2 developments inside
-
Pfizer, Johnson & Johnson, and Merck are facing significant industry pressures due to patent cliffs and market pricing demands.Some support1 report
-
Protagonist Therapeutics co-discovered ICOTYDE with Johnson & Johnson and subsequently licensed the technology to Janssen Biotech.Well supported7 reports1 development inside
-
J&J and Janssen Biotech jointly won summary judgment in a Virginia court regarding J&J's acquisition, with FTC filing an amicus brief.Some support1 report
-
AbbVie, Abbott Laboratories, and Johnson & Johnson were recommended as dividend stocks for retirees, operating in the healthcare sector.Some support2 reports1 development inside
Earlier this month
-
Johnson & Johnson and Compass Pathways are both involved in the advanced psychedelic therapy market, currently submitting applications for COMP360 approval.Some support1 report
-
A study examined the dividend policy performance of P&G and J&J, contrasting them with growth stocks like Nvidia and Micron.Some support3 reports
-
J&J plans heavy US investment and growth, including a new facility in North Carolina, as discussed by CEO Joaquin Duato.Some support2 reports1 development inside
-
Joaquin Duato guides Johnson & Johnson to achieve double-digit growth.Some support1 report
-
The event covers disparate news items involving Wipro managing AI systems, SAP usage, and Kumar judging innovation awards.Speculative1 report1 development inside
-
MarketBeat listed UnitedHealth Group, Eli Lilly and Company, Moderna, Thermo Fisher Scientific Inc., Johnson & Johnson, and Illumina as stocks to watch.Some support1 report
-
Johnson & Johnson, BDX, and Universal Health Realty Income Trust were identified as attractive dividend-paying healthcare stocks.Some support1 report1 development inside
-
Johnson & Johnson and Realty Income are noted for competing dividend investment vehicles.Some support1 report
-
An ETF holds shares of Johnson & Johnson, ExxonMobil, and JPMorgan Chase.Some support1 report
-
Johnson & Johnson is reportedly considering a sale of its orthopedics business unit within DePuy Synthes.Some support2 reports
-
Johnson & Johnson developed JNJ-5120/PIPE-307 under a global license.Some support3 reports
-
Biosimilar erosion is impacting market share, and AbbVie, Procter & Gamble, and Johnson & Johnson are noted as major consumer goods players.Some support2 reports
-
Shipping disruptions are causing procedural changes and increased competition among medical device manufacturers Johnson & Johnson and Boston Scientific.Some support2 reports
-
Financial planning compares private income from dividend-paying companies like Procter & Gamble and Johnson & Johnson against government benefits such as Social Security.Some support1 report2 developments inside
-
Both Procter & Gamble and Johnson & Johnson demonstrated financial resilience during market downturns.Some support1 report
-
Several major companies, including Alphabet, Apple, Microsoft, and Amazon, were reported as having significant institutional holdings.Some support1 report
-
Johnson & Johnson and Mindray launched innovative products at the CIFTIS conference held in Beijing.Some support1 report
-
Dividend yields for companies like P&G and J&J are benchmarked against Fed targets, serving investors needing financial advice.Some support1 report
-
Johnson & Johnson highlighted growth opportunities within the MedTech sector.Some support1 report
-
Wendy gained experience at Johnson & Johnson and Amazon before joining Glanbia.Some support1 report
-
Johnson & Johnson and Nike are multinational members of a trade chamber, while Sakari Puisto serves as Finland's minister of economic affairs.Some support15 reports
-
Several healthcare ETFs hold major pharmaceutical companies like Eli Lilly, J&J, and Novo Nordisk as top 3 positions, leading to competition for investor capital.Some support1 report1 development inside
-
Johnson & Johnson gained approval for its Icotyde treatment in the China market.Some support1 report
-
Report covers clinical trials for Mycosis Fungoides involving Bristol-Myers Squibb, Johnson & Johnson, Merck, and Novartis.Some support3 reports1 development inside
-
Schmid, who is the MedTech Chairman for Johnson & Johnson, is involved in a fireside chat hosted by Wells Fargo.Some support1 report
-
Major healthcare companies like BMS, J&J, and EL are facing market pressures, including biosimilar erosion, while maintaining strong sector positions.Some support1 report1 development inside
-
Bristol-Myers Squibb and Johnson & Johnson are both companies that are currently targets of LB Pharmaceuticals.Some support1 report
-
Johnson & Johnson and Mastercard are currently top holdings within the JEPI investment fund.Some support1 report
-
Medicare premiums are impacting the dividend yields of Johnson & Johnson.Some support1 report1 development inside
-
Rising premiums are creating financial pressure, necessitating dividend coverage for PepsiCo, Johnson & Johnson, and the impact of Medicare.Some support2 reports
-
Peter Lebowitz, formerly of J&J R&D, was appointed to the Board of Directors of Flare Therapeutics Inc.Some support1 report
-
UBS began coverage of Johnson & Johnson.Some support1 report
-
Protagonist Therapeutics and Takeda Pharmaceutical Company entered a strategic partnership regarding the Rusfertide drug candidate, while Citi initiated coverage with a Buy rating.Some support6 reports1 development inside
-
AbbVie and Johnson & Johnson are top exposures in the VYM ETF, which itself holds Microsoft.Some support5 reports
-
Johnson & Johnson and Siemens Healthineers launched new products, including SOUNDSTAR CRYSTAL and AcuNav catheter, in the U.S. market.Some support1 report
-
Legend Biotech and Johnson & Johnson announced their collaboration on CARVYKTI, while Legend Biotech also utilized LinkedIn for professional presence.Well supported5 reports
-
HSBC provided a buy rating and price target for Johnson & Johnson, while Morgan Stanley raised its price objective to $294.00. The company also filed required 13F reports with the SEC.Some support1 report
-
Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.Some support2 reports1 development inside
-
Johnson & Johnson is scheduled to present at a major industry summit, likely related to the Deutsche Bank Healthcare Summit.Some support2 reports
-
Johnson & Johnson and PepsiCo were classified as elite Dividend Kings and featured as attractive dividend stocks.Some support3 reports1 development inside
-
C3.ai closed enterprise agreements with Heidelberg Materials, Ford Motor Company, Johnson & Johnson, Defense Logistics Agency, and Holcim.Some support3 reports
-
Procter & Gamble, Johnson & Johnson, Coca-Cola, and Verizon are discussed as income-generating companies referenced in dividend investment strategies.Some support5 reports1 development inside
-
Mike Minogue is running for the governorship of Massachusetts, while Johnson & Johnson purchased Abiomed in 2022 for $17 billion.Some support2 reports
-
Kimberly-Clark is acquiring Kenvue's consumer health business, which includes Listerine and Neutrogena staples, following Kenvue's spin-off from J&J.Some support3 reports1 development inside
-
Johnson & Johnson and Fisher Investments were used as a case study for retirement income planning.Some support1 report
-
MidFirst Bank acquired a new stake in Johnson & Johnson shares on June 20, 2026.Well supported3 reports
No events began in the chosen period. Widen it, or reset.
Around Johnson & Johnson this week
News at the entities that move Johnson & Johnson most-
Eli Lilly and Company OperationalExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Moves Johnson & Johnson
-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Johnson & Johnson
-
Intuitive Surgical OperationalMedtronic is ramping up its Hugo RAS system to compete with Intuitive Surgical, while its neuroscience unit faces competitive pressure from Stryker and Globus Medical.Moves Johnson & Johnson
-
Kenvue StructuralIWS filed required documents with the Securities and Exchange Commission on June 6, 2026, detailing institutional investor holdings.Moves Johnson & Johnson
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Johnson & Johnson
-
Amundi TransactionalAmundi increased its stock holding in Amazon.com, Inc. on September 28, 2026.Moves Johnson & Johnson
Connections
The 40 strongest of 553, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Berkshire Hathaway Structural
Berkshire Hathaway historically owned Johnson & Johnson.
-
Medtech Structural
Medtech operates as a core, dependent segment and subsidiary within Johnson & Johnson's corporate structure.
-
Eli Lilly and Company Operational
The two pharmaceutical companies are engaged in direct, high-stakes market competition across various therapeutic and growth segments.
-
Legend Biotech Structural
Legend Biotech and Johnson & Johnson maintain a deep structural partnership, co-developing and supplying the CARVYKTI treatment, cemented by J&J's investment in Legend's portfolio.
-
Joaquin Duato Structural
Joaquin Duato holds the executive leadership roles of CEO and Chairman at Johnson & Johnson.
-
SEC Structural
Johnson & Johnson is subject to mandatory financial and disclosure regulations enforced by the SEC.
-
Howard Reid Structural
Howard Reid serves as the VP of corporate brand at Johnson & Johnson.
-
Intuitive Surgical Operational
Intuitive Surgical and Johnson & Johnson are active market rivals competing for dominance in the minimally invasive and robotic surgery sectors.
Show all 40 connections
-
Kenvue Structural
Kenvue was formed through the spin-off of its consumer health business unit from Johnson & Johnson.
-
FDA Structural
The FDA functions as the mandatory regulatory gatekeeper, evaluating and granting market access approvals for Johnson & Johnson's medical and pharmaceutical products.
-
Zymeworks Structural
J&J relies on Zymeworks' proprietary technology platform for the development and production of pasritamig.
-
Boston Scientific Operational
Both companies are major competitors in the medical device and endoscopy markets.
-
Amgen Operational
Johnson & Johnson and Amgen are active competitors in the biopharma sector, vying for market leadership in immunology and bispecific antibodies.
-
Pfizer Operational
Pfizer and Johnson & Johnson are major, publicly traded competitors in the global pharmaceutical market, facing shared market pressures like patent cliffs and pricing scrutiny.
-
Genmab Structural
Genmab receives royalty revenue from Johnson & Johnson's commercialization of daratumumab under an exclusive license agreement.
-
Procter & Gamble Operational
Both companies are direct competitors in the consumer staples market, frequently compared based on dividend growth and financial resilience.
-
AbioMed Structural
Johnson & Johnson acquired AbioMed in 2022 and operates it as a subsidiary.
-
Donald Trump Operational
Trump's political actions, including tariff threats and trade strategy, directly influence J&J's market outlook and operational planning, while J&J is mentioned in Trump's financial disclosures.
-
Abbott Laboratories Operational
Both companies are major healthcare giants that actively compete for market share through product innovation and strategic moves.
-
Amundi Transactional
Amundi increased its investment holdings in Johnson & Johnson shares during the third quarter of 2026.
-
Janssen Biotech Structural
Janssen Biotech operates as a licensed entity under Johnson & Johnson.
-
Vanguard Structural
Vanguard holds shares of Johnson & Johnson as part of its investment portfolio.
-
Jim Cramer Operational
Jim Cramer provides financial commentary and investment recommendations on Johnson & Johnson's stock performance, influencing market sentiment.
-
AbbVie Operational
AbbVie and Johnson & Johnson are direct competitors in the biopharmaceutical sector, vying for market share in oncology and immunology.
-
HAAS Structural
Erik Haas serves as the Vice President of Litigation for Johnson & Johnson.
-
Idorsia Transactional
Idorsia was acquired by Johnson & Johnson, leading to its subsequent spin-off.
-
Vision Structural
Johnson & Johnson is providing investment to strengthen Vision's operations and business unit.
-
Daiwa Securities Group Operational
Daiwa Securities Group actively influences Johnson & Johnson's market valuation through analyst reports and price target adjustments.
-
Volt Structural
Johnson & Johnson MedTech utilizes and expands its new systems based on the Volt platform.
-
Viswanathan Transactional
Viswanathan previously held a sales and marketing role at Johnson & Johnson.
-
Jacksonville Structural
Johnson & Johnson is expanding its U.S. Vision manufacturing operations in Jacksonville with a $1 billion investment.
-
AC Immune Structural
AC Immune collaborates with Johnson & Johnson on drug evaluation, with milestone payments triggered by trial progress.
-
Protagonist Therapeutics (United States) Structural
Protagonist Therapeutics and Johnson & Johnson maintain a strategic partnership involving the joint development and licensing of the drug Icotrokinra.
-
Acuvue Structural
Johnson & Johnson operates and launches products under the Acuvue brand.
-
Europe Operational
Johnson & Johnson actively launches, approves, and expands product lines within the European market bloc.
-
John Reed Structural
John Reed serves as an Executive Vice President at Johnson & Johnson and is a member of the Executive Committee.
-
SPDR Structural
SPDR ETF holds Johnson & Johnson as a major investment position, representing a formal ownership stake.
-
company Structural
Johnson & Johnson maintains a structural dependency on the entity 'company' through receiving royalties from a collaboration.
-
Merck Operational
Johnson & Johnson and Merck are major pharmaceutical companies actively competing in specialized drug markets like oncology and PAH.
-
Tom Cavanaugh Structural
Forecasted leadership role of Tom Cavanaugh within the Innovative Medicine division of Johnson & Johnson.
History
Events by the month they beganSeptember 2026
38 events- Healthcare architecture is rapidly changing, with robotic procedures underway in Riyadh involving major players like Johnson & Johnson, Mayo Clinic, and Cleveland Clinic.
- The CBO reported an $8.8 billion handout in OBBB, which weakened Medicare drug price negotiation. Bryan Steil voted for the bill benefiting Big Pharma, after receiving donations from lobbyists.
- Johnson & Johnson announced successful Phase 2 trial data for CARVYKTI in the multiple myeloma therapy market.
- Johnson & Johnson and Recordati Industria Chimica E Farmaceutica are noted as large-cap healthcare companies.
- Johnson & Johnson, JPMorgan Chase, and AbbVie are dividend payers in the VYM fund.
- Nanobiotix and Johnson & Johnson are collaborating on nanotherapeutics. Laurent Levy is the CEO of Nanobiotix.
- Pfizer, Johnson & Johnson, and Merck are facing significant industry pressures due to patent cliffs and market pricing demands.
- J&J and Janssen Biotech jointly won summary judgment in a Virginia court regarding J&J's acquisition, with FTC filing an amicus brief.
- Johnson & Johnson and Compass Pathways are both involved in the advanced psychedelic therapy market, currently submitting applications for COMP360 approval.
- A study examined the dividend policy performance of P&G and J&J, contrasting them with growth stocks like Nvidia and Micron.
- Joaquin Duato guides Johnson & Johnson to achieve double-digit growth.
- MarketBeat listed UnitedHealth Group, Eli Lilly and Company, Moderna, Thermo Fisher Scientific Inc., Johnson & Johnson, and Illumina as stocks to watch.
- Johnson & Johnson and Realty Income are noted for competing dividend investment vehicles.
- An ETF holds shares of Johnson & Johnson, ExxonMobil, and JPMorgan Chase.
- Johnson & Johnson is reportedly considering a sale of its orthopedics business unit within DePuy Synthes.
- Johnson & Johnson developed JNJ-5120/PIPE-307 under a global license.
- Biosimilar erosion is impacting market share, and AbbVie, Procter & Gamble, and Johnson & Johnson are noted as major consumer goods players.
- Shipping disruptions are causing procedural changes and increased competition among medical device manufacturers Johnson & Johnson and Boston Scientific.
- Both Procter & Gamble and Johnson & Johnson demonstrated financial resilience during market downturns.
- Several major companies, including Alphabet, Apple, Microsoft, and Amazon, were reported as having significant institutional holdings.
- Johnson & Johnson and Mindray launched innovative products at the CIFTIS conference held in Beijing.
- Dividend yields for companies like P&G and J&J are benchmarked against Fed targets, serving investors needing financial advice.
- Johnson & Johnson highlighted growth opportunities within the MedTech sector.
- Wendy gained experience at Johnson & Johnson and Amazon before joining Glanbia.
- Johnson & Johnson and Nike are multinational members of a trade chamber, while Sakari Puisto serves as Finland's minister of economic affairs.
- Johnson & Johnson gained approval for its Icotyde treatment in the China market.
- Schmid, who is the MedTech Chairman for Johnson & Johnson, is involved in a fireside chat hosted by Wells Fargo.
- Bristol-Myers Squibb and Johnson & Johnson are both companies that are currently targets of LB Pharmaceuticals.
- Johnson & Johnson and Mastercard are currently top holdings within the JEPI investment fund.
- Rising premiums are creating financial pressure, necessitating dividend coverage for PepsiCo, Johnson & Johnson, and the impact of Medicare.
- Peter Lebowitz, formerly of J&J R&D, was appointed to the Board of Directors of Flare Therapeutics Inc.
- UBS began coverage of Johnson & Johnson.
- AbbVie and Johnson & Johnson are top exposures in the VYM ETF, which itself holds Microsoft.
- Johnson & Johnson and Siemens Healthineers launched new products, including SOUNDSTAR CRYSTAL and AcuNav catheter, in the U.S. market.
- HSBC provided a buy rating and price target for Johnson & Johnson, while Morgan Stanley raised its price objective to $294.00. The company also filed required 13F reports with the SEC.
- Johnson & Johnson is scheduled to present at a major industry summit, likely related to the Deutsche Bank Healthcare Summit.
- C3.ai closed enterprise agreements with Heidelberg Materials, Ford Motor Company, Johnson & Johnson, Defense Logistics Agency, and Holcim.
- Mike Minogue is running for the governorship of Massachusetts, while Johnson & Johnson purchased Abiomed in 2022 for $17 billion.
August 2026
5 events- Financial planning compares private income from dividend-paying companies like Procter & Gamble and Johnson & Johnson against government benefits such as Social Security.
- Major healthcare companies like BMS, J&J, and EL are facing market pressures, including biosimilar erosion, while maintaining strong sector positions.
- Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.
- Procter & Gamble, Johnson & Johnson, Coca-Cola, and Verizon are discussed as income-generating companies referenced in dividend investment strategies.
- Johnson & Johnson and Fisher Investments were used as a case study for retirement income planning.
July 2026
2 eventsShow 1 earlier month
June 2026
15 events- P&G, Johnson & Johnson, and Coca-Cola are noted as dividend growth stocks, coinciding with SEC requirements for fiduciaries to prioritize interests.
- Johnson & Johnson separated its Consumer Health business into Kenvue on August 25, 2025.
- Johnson & Johnson, UnitedHealth Group, and Intuitive Surgical are noted as major players in the high-volume U.S. healthcare sector.
- RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.
- Protagonist Therapeutics co-discovered ICOTYDE with Johnson & Johnson and subsequently licensed the technology to Janssen Biotech.
- AbbVie, Abbott Laboratories, and Johnson & Johnson were recommended as dividend stocks for retirees, operating in the healthcare sector.
- J&J plans heavy US investment and growth, including a new facility in North Carolina, as discussed by CEO Joaquin Duato.
- The event covers disparate news items involving Wipro managing AI systems, SAP usage, and Kumar judging innovation awards.
- Johnson & Johnson, BDX, and Universal Health Realty Income Trust were identified as attractive dividend-paying healthcare stocks.
- Several healthcare ETFs hold major pharmaceutical companies like Eli Lilly, J&J, and Novo Nordisk as top 3 positions, leading to competition for investor capital.
- Report covers clinical trials for Mycosis Fungoides involving Bristol-Myers Squibb, Johnson & Johnson, Merck, and Novartis.
- Protagonist Therapeutics and Takeda Pharmaceutical Company entered a strategic partnership regarding the Rusfertide drug candidate, while Citi initiated coverage with a Buy rating.
- Legend Biotech and Johnson & Johnson announced their collaboration on CARVYKTI, while Legend Biotech also utilized LinkedIn for professional presence.
- Johnson & Johnson and PepsiCo were classified as elite Dividend Kings and featured as attractive dividend stocks.
- MidFirst Bank acquired a new stake in Johnson & Johnson shares on June 20, 2026.